- Previous close
117.28 - Open
117.28 - Bid 111.51 x 38800
- Ask 118.44 x 36900
- Day's range
117.28 - 117.28 - 52-week range
90.24 - 123.55 - Volume
30 - Avg. Volume
3,148 - Market cap (intra-day)
232.645B - Beta (5Y monthly) 0.50
- PE ratio (TTM)
22.12 - EPS (TTM)
4.89 - Earnings date 29 Oct 2024
- Forward dividend & yield 3.76 (3.48%)
- Ex-dividend date 7 Mar 2024
- 1y target est
--
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
www.novartis.com76,057
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Drug Manufacturers - General
Industry
Recent news: NVSEF
View more
Performance overview: NVSEF
Trailing total returns as of 29/10/2024, which may include dividends or other distributions. Benchmark is
.YTD return
1-year return
3-year return
5-year return
Compare to: NVSEF
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: NVSEF
View moreValuation measures
Market cap
232.65B
Enterprise value
253.20B
Trailing P/E
22.12
Forward P/E
13.32
PEG ratio (5-yr expected)
3.92
Price/sales (ttm)
4.57
Price/book (mrq)
5.25
Enterprise value/revenue
5.18
Enterprise value/EBITDA
13.34
Financial highlights
Profitability and income statement
Profit margin
33.11%
Return on assets (ttm)
8.86%
Return on equity (ttm)
21.50%
Revenue (ttm)
48.86B
Net income avi to common (ttm)
10.08B
Diluted EPS (ttm)
4.89
Balance sheet and cash flow
Total cash (mrq)
8.43B
Total debt/equity (mrq)
69.18%
Levered free cash flow (ttm)
14.81B